Logo for Knight Therapeutics Inc

Knight Therapeutics Investor Relations Material

Latest events

Logo for Knight Therapeutics Inc

Q1 2024

Knight Therapeutics
Logo for Knight Therapeutics

Q1 2024

9 May, 2024
Logo for Knight Therapeutics

Q4 2023

21 Mar, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Knight Therapeutics Inc

Access all reports
Segment Data
Access more data
Revenue by
Geography
Brazil
Argentina
Colombia
Rest of LATAM
Other
Expenses by
Financials
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Impavido (miltefosine), an oral antifungal product for the treatment of visceral, cutaneous, and mucosal leishmaniasis; Macrilen (macimorelin), a growth hormone secretagogue receptor agonist for use in the investigational stimulation testing of adults with adult growth hormone deficiency; Probuphine (buprenorphine) implant for subdermal administration to facilitate remission from opioid use disorder; Neuragen or NeurogesX topical research portfolio consisting of Qutenza (capsaicin 8% patch) for neuropathic pain indication in Canada.